Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Average Recommendation of “Moderate Buy” from Analysts

Zealand Pharma A/S (OTCMKTS:ZLDPF) has earned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and three have given a strong buy recommendation to the company.

A number of analysts have recently commented on ZLDPF shares. Wolfe Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Berenberg Bank downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Finally, BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th.

Zealand Pharma A/S Stock Performance

OTCMKTS:ZLDPF opened at $44.75 on Tuesday. The company has a market capitalization of $3.20 billion, a P/E ratio of 3.32 and a beta of 0.86. The firm has a fifty day simple moving average of $47.89 and a 200-day simple moving average of $56.52. Zealand Pharma A/S has a 12 month low of $35.93 and a 12 month high of $83.12. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.50. The company had revenue of $5.33 million during the quarter, compared to the consensus estimate of $2.81 million. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. On average, equities research analysts anticipate that Zealand Pharma A/S will post 2.37 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.